Took Corona Vaccine: You life might be at risk ????

British pharmaceutical giant AstraZeneca has shockingly acknowledged in court documents that its COVID-19 vaccine, Covishield, can cause a rare but serious condition known as Thrombosis with Thrombocytopenia Syndrome (TTS). This condition leads to blood clots and a low platelet count, posing significant health risks.

This admission came to light during a class action lawsuit in the UK, where victims are seeking up to ￡100 million in damages for deaths and severe injuries allegedly caused by the vaccine. One of the claimants, Jamie Scott, reported suffering a permanent brain injury due to a blood clot after receiving the vaccine in April 2021, which dramatically affected his ability to work and nearly resulted in his death.

Despite AstraZeneca's previous stance in 2023, where they denied a generic causal link between the vaccine and TTS, recent court filings indicate an acceptance of the possibility of such side effects occurring, although they emphasized that TTS can also occur independently of vaccination. The company maintains that whether the vaccine caused TTS in specific individuals will require expert testimony.

In response to the allegations, AstraZeneca has defended the integrity and efficacy of the Covishield vaccine, disputing claims that it is "defective" or that its benefits were "vastly overstated." However, the acknowledgment in court marks a significant shift in the narrative surrounding the vaccine's safety profile.

The controversy surrounding Covishield led to its suspension or outright ban in several countries worldwide, including Denmark, Ireland, Thailand, and Canada, among others, primarily due to reported cases of blood clots post-vaccination.

The World Health Organization (WHO) has continued to recommend the AstraZeneca vaccine, stating that its benefits outweigh the risks and urging that vaccinations proceed. Nonetheless, the ongoing legal challenges and AstraZeneca's admission highlight the complexities and responsibilities of vaccine manufacturers in addressing potential adverse effects.

Follow ProDot Group for more